
James J Mcgough

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1440868/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Trigeminal Nerve Stimulation for Attention-Deficit/Hyperactivity Disorder: Cognitive and Electroencephalographic Predictors of Treatment Response. Journal of the American Academy of Child and Adolescent Psychiatry, 2021, 60, 856-864.e1.	0.5	21
2	Inhibitory control in youth with Tourette's Disorder, attention-deficit/hyperactivity disorder and their combination and predictors of objective tic suppressibility. Psychiatry Research, 2021, 304, 114163.	3.3	8
3	Reply to "Transcutaneous electric currents to target the peripheral and central nervous system in children with attention deficit hyperactivity disorder― Clinical Neurophysiology, 2019, 130, 2008-2009.	1.5	3
4	Double-Blind, Sham-Controlled, Pilot Study of Trigeminal Nerve Stimulation for Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2019, 58, 403-411.e3.	0.5	71
5	Are the components of social reciprocity transdiagnostic across pediatric neurodevelopmental disorders? Evidence for common and disorder-specific social impairments. Psychiatry Research, 2018, 264, 119-123.	3.3	11
6	Hemispheric brain asymmetry differences in youths with attention-deficit/hyperactivity disorder. NeuroImage: Clinical, 2018, 18, 744-752.	2.7	35
7	The Effect of Neurocognitive Function on Math Computation in Pediatric ADHD: Moderating Influences of Anxious Perfectionism and Gender. Child Psychiatry and Human Development, 2018, 49, 822-832.	1.9	2
8	Parsing heterogeneity in attentionâ€deficit hyperactivity disorder using EEG â€based subgroups. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2018, 59, 223-231.	5.2	50
9	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	12.6	1,085
10	Effects of d-Methylphenidate, Guanfacine, and Their Combination on Electroencephalogram Resting State Spectral Power in Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, 674-682.e1.	0.5	28
11	Treatment Controversies in Adult ADHD. American Journal of Psychiatry, 2016, 173, 960-966.	7.2	29
12	New Insights From the MTA: Who Outgrows Attention-Deficit/Hyperactivity Disorder and What Becomes of Those Who Don't?. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, 925-926.	0.5	2
13	Combined Stimulant and Guanfacine Administration in Attention-Deficit/Hyperactivity Disorder: A Controlled, Comparative Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, 657-666.e1.	0.5	37
14	Neuropsychological and dimensional behavioral trait profiles in Costa Rican ADHD sib pairs: Potential intermediate phenotypes for genetic studies. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2015, 168, 247-257.	1.7	4
15	An Eight-week, Open-trial, Pilot Feasibility Study of Trigeminal Nerve Stimulation in Youth With Attention-deficit/Hyperactivity Disorder. Brain Stimulation, 2015, 8, 299-304.	1.6	40
16	Chronic Non-Episodic Irritability in Childhood: Current and Future Challenges. American Journal of Psychiatry, 2014, 171, 607-610.	7.2	5
17	Neurophysiologic predictors of response to atomoxetine in young adults with attention deficit hyperactivity disorder: A pilot project. Journal of Psychiatric Research, 2014, 54, 11-18.	3.1	18
18	Neural activation during response inhibition in adult attention-deficit/hyperactivity disorder: Preliminary findings on the effects of medication and symptom severity. Psychiatry Research - Neuroimaging, 2014, 222, 17-28.	1.8	39

JAMES J MCGOUGH

#	Article	IF	CITATIONS
19	Frontostriatal neuroimaging findings differ in patients with bipolar disorder who have or do not have ADHD comorbidity. Journal of Affective Disorders, 2013, 147, 389-396.	4.1	16
20	A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of α4β2 Agonist ABT-894 in Adults with ADHD. Neuropsychopharmacology, 2013, 38, 405-413.	5.4	48
21	A Potential Electroencephalography and Cognitive Biosignature for the Child Behavior Checklist–Dysregulation Profile. Journal of the American Academy of Child and Adolescent Psychiatry, 2013, 52, 1173-1182.	0.5	21
22	Characteristics and comorbidity of ADHD sib pairs in the Central Valley of Costa Rica. Comprehensive Psychiatry, 2012, 53, 379-386.	3.1	8
23	Attention deficit hyperactivity disorder pharmacogenetics: the dopamine transporter and D4 receptor. Pharmacogenomics, 2012, 13, 365-368.	1.3	17
24	Genome-wide association study of blood pressure response to methylphenidate treatment of attention-deficit/hyperactivity disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 466-472.	4.8	24
25	Familial Clustering and DRD4 Effects on Electroencephalogram Measures in Multiplex Families With Attention Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2010, 49, 368-377.	0.5	48
26	Progress and Promise of Attention-Deficit Hyperactivity Disorder Pharmacogenetics. CNS Drugs, 2010, 24, 99-117.	5.9	80
27	Familial clustering and DRD4 effects on electroencephalogram measures in multiplex families with attention deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2010, 49, 368-77.	0.5	37
28	Cortical activity patterns in ADHD during arousal, activation and sustained attention. Neuropsychologia, 2009, 47, 2114-2119.	1.6	121
29	A Candidate Gene Analysis of Methylphenidate Response in Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2009, 48, 1155-1164.	0.5	74
30	Estimating the size of treatment effects: moving beyond p values. Psychiatry, 2009, 6, 21-9.	0.3	81
31	Association of the cannabinoid receptor gene (CNR1) with ADHD and postâ€traumatic stress disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 1488-1494.	1.7	99
32	The Pharmacogenomic Era: Promise for Personalizing Attention Deficit Hyperactivity Disorder Therapy. Child and Adolescent Psychiatric Clinics of North America, 2008, 17, 475-490.	1.9	48
33	CBCL Pediatric Bipolar Disorder Profile and ADHD: Comorbidity and Quantitative Trait Loci Analysis. Journal of the American Academy of Child and Adolescent Psychiatry, 2008, 47, 1151-1157.	0.5	64
34	Pharmacokinetics of Methylphenidate Transdermal System (MTS): Results from a Laboratory Classroom Study. Journal of Child and Adolescent Psychopharmacology, 2008, 18, 355-364.	1.3	26
35	Long-Term Effectiveness and Safety of Lisdexamfetamine Dimesylate in School-Aged Children with Attention-Deficit/Hyperactivity Disorder. CNS Spectrums, 2008, 13, 614-620.	1.2	79
36	Effects of Source of DNA on Genotyping Success Rates and Allele Percentages in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). Journal of Child and Adolescent Psychopharmacology, 2007, 17, 635-645.	1.3	8

JAMES J MCGOUGH

#	Article	IF	CITATIONS
37	Effectiveness of Methylphenidate in the 10-Month Continuation Phase of the Preschoolers with ADHD Treatment Study (PATS). Journal of Child and Adolescent Psychopharmacology, 2007, 17, 593-603.	1.3	55
38	Executive Functioning Among Finnish Adolescents With Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2007, 46, 1594-1604.	0.5	55
39	Prevalence and Psychiatric Comorbidity of Attention-Deficit/Hyperactivity Disorder in an Adolescent Finnish Population. Journal of the American Academy of Child and Adolescent Psychiatry, 2007, 46, 1575-1583.	0.5	141
40	ADHD Pharmacogenomics: Past, Present, and Future. Medical Psychiatry, 2007, , 359-372.	0.2	0
41	Relationship of Family Environment and Parental Psychiatric Diagnosis to Impairment in ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 346-354.	0.5	92
42	A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder. Clinical Therapeutics, 2006, 28, 280-293.	2.5	24
43	Adult Attention Deficit Hyperactivity Disorder: Moving Beyond DSM-IV. American Journal of Psychiatry, 2006, 163, 1673-1675.	7.2	26
44	Atypical brain laterality in adults with ADHD during dichotic listening for emotional intonation and words. Neuropsychologia, 2006, 44, 896-904.	1.6	36
45	A Randomized, Double-Blind, Placebo-Controlled, Laboratory Classroom Assessment of Methylphenidate Transdermal System in Children With ADHD. Journal of Attention Disorders, 2006, 9, 476-485.	2.6	106
46	Once-Daily OROS® Methylphenidate Is Safe and Well Tolerated in Adolescents With Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2006, 16, 351-356.	1.3	34
47	Psychiatric Comorbidity in Adult Attention Deficit Hyperactivity Disorder: Findings From Multiplex Families. American Journal of Psychiatry, 2005, 162, 1621-1627.	7.2	336
48	Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder. Expert Review of Neurotherapeutics, 2005, 5, 437-441.	2.8	17
49	Short- and Long-Term Cardiovascular Effects of Mixed Amphetamine Salts Extended Release in Children. Journal of Pediatrics, 2005, 147, 348-354.	1.8	76
50	Attention-Deficit/Hyperactivity Disorder Pharmacogenomics. Biological Psychiatry, 2005, 57, 1367-1373.	1.3	86
51	Long-Term Tolerability and Effectiveness of Once-Daily Mixed Amphetamine Salts (Adderall XR) in Children With ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 2005, 44, 530-538.	0.5	79
52	Diagnostic Controversies in Adult Attention Deficit Hyperactivity Disorder. American Journal of Psychiatry, 2004, 161, 1948-1956.	7.2	316
53	New drugs for the treatment of attention-deficit/hyperactivity disorder. Expert Opinion on Emerging Drugs, 2004, 9, 293-302.	2.4	14
54	Pharmacokinetics of SLI381 (ADDERALL XR), an Extended-Release Formulation of Adderall. Journal of the American Academy of Child and Adolescent Psychiatry, 2003, 42, 684-691.	0.5	70

#	Article	IF	CITATIONS
55	Analog Classroom Assessment of a Once-Daily Mixed Amphetamine Formulation, SLI381 (ADDERALL XR), in Children With ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 2003, 42, 673-683.	0.5	118
56	A Genomewide Scan for Attention-Deficit/Hyperactivity Disorder in an Extended Sample: Suggestive Linkage on 17p11. American Journal of Human Genetics, 2003, 72, 1268-1279.	6.2	206
57	Assessment of attention deficit hyperactivity disorder: a review of recent literature. Current Opinion in Pediatrics, 2000, 12, 319-324.	2.0	25
58	Familial Clustering of Symptoms and Disruptive Behaviors in Multiplex Families With Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2000, 39, 1135-1143.	0.5	152